



Larka

Press release

Merger & Acquisition

28th of July, 2021

**Larka provided Afinum and SHS
with a **Vendor Commercial
Due-Diligence** to support exit
of evitria.**

Afinum

SHS 

evitria





We are proud to have supported Afinum, SHS and evitria in this successful sale process. Afinum and SHS have

built together with evitria management a global leader in transient CHO cell antibody expression within a short period of time and it's been rewarding to have interactions with such sharp and experienced people all along the process. I'm convinced evitria's strong positioning and very successful growth path will continue to accelerate in the future, especially in conjunction with the new owner Atlas Antibodies.

Pierre-Anthony Brioir, Director at Larka.

Vendor Due-Diligence

Vendor Due-Diligences within the BioPharma space are crucial to jump-start a successful auction process, but also much more complex than within other universe.

With close to **30 years** of experience and an unrivalled team of senior-level experts, our Biotech & Pharma industry knowledge is matchless.

We provide sellers with an **exhaustive** and **fact-based** story of their asset, ultimately showing its **true value** to increase attractivity and simplify buy-side DD teams' work.

Contact

Pierre-Anthony Brioir, Director
+33 650 630 286
pabrioir@larka.com

Adrien Chalmont, Manager
+33 621 006 115
achalmont@larka.com

Larka is thrilled to announce that it performed the Vendor Commercial Due-Diligence to support Afinum and SHS on their exit process of evitria, a global leading service provider specialized in transient antibody expression.



It has been a true pleasure to collaborate with Larka on this process, and I would definitely recommend working with them. What really stands out for me is their ability to combine science with business expertise within a complex niche market like transient antibody expression. Coupled with their data-driven methodologies and broad network of market-specific decision-makers, they've been able to form a consistent story of evitria within a really short timeframe.

Christian Eberle, CEO at evitria.



After a successful holding period for Afinum, we are glad to complete our journey with evitria in the best possible way, for us, and for every stakeholder. We have been highly impressed with Larka's antibody field expertise and the quality of the work they have delivered within very challenging timelines. Thank you to Larka's M&A team for their support and ability to demonstrate evitria's full potential throughout this process.

Philipp Schülin, Senior Partner at Afinum.

Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This

transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.

Since its inception in 2010, evitria has been singularly focused on transient expression of recombinant antibodies in CHO cells. This long-standing and deep focus allows the company to deliver antibodies of exceptional quality with outstanding service levels with respect to turnaround time and material quantity. With a track record of more than 75,000 transfections performed and more than 12,000 antibody-based molecules purified, **evitria is a trusted partner for full outsourcing of antibody production** for research purposes, to manage capacity bottlenecks, or to pursue single projects.

About Afinum

Afinum is an independent investment firm with offices in Munich, Zurich and Hongkong, with a focus on majority investments in successful mid-sized companies and succession situations in Germany, Switzerland and Austria. Afinum takes on a sustainable approach to value creation and partners with management teams to pursue ambitious organic and inorganic growth strategies.

For more information, please visit www.afinum.de

About SHS Capital

SHS Capital, founded in 1993 and located in Tübingen, Germany, is a dedicated healthcare investment fund. Following the slogan "Building European Healthcare Champions", the focus of its investments is on expansion financing, shareholder changes and succession situations in the healthcare industry. In doing so, SHS takes both minority and majority stakes. SHS is currently investing from its fifth fund, which was launched in 2018.

For more information, please visit www.shs-capital.eu

About Evitria

Founded in 2010 in Zurich, Switzerland, evitria is an expert provider of antibody expression services, with clients ranging from academic laboratories and small biotech start-ups to global biopharmaceutical companies. evitria is deeply specialized in CHO-based transient expression of antibodies, including bispecific and fusion antibodies

For more information, please visit www.evitria.com

About Larka

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit www.larka.com